PureTech Health
Robert Lyne is an accomplished executive with extensive experience in the biotechnology and legal sectors. Currently serving as Chief Portfolio Officer at PureTech Health since February 2024, Robert Lyne previously held multiple leadership roles at Arix Bioscience plc, including Chief Executive Officer, Interim Chief Executive Officer, Chief Operating Officer & General Counsel, and General Counsel from July 2017 to December 2023. Additionally, Robert Lyne was a Legal Advisor at Imperial Innovations from October 2014 to June 2017, following a tenure as an Associate at Bird & Bird LLP from September 2008 to September 2014. Academically, Robert Lyne holds a BA in Philosophy, Politics, and Economics from the University of Oxford and a GDL & LPC in Law from Oxford Brookes University.
This person is not in any teams
This person is not in any offices
PureTech Health
4 followers
PureTech (Nasdaq: PRTC, LSE: PRTC) is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others.